In a prospective study, the cytomegalovirus (CMV) pp65 antigenemia assay was compared with detection of CMV by blood culture in 67 consecutive CMV-seropositive patients undergoing autologous marrow or peripheral blood stem cell transplantation. Antigenemia occurred in 26 patients (38.8%) a median of 33 days (range, 12-74) after transplant. Viremia was detected in 5 patients (7.5%) a median of 30 days (range, 12-74) after transplant and was treated with ganciclovir in 3. Antigenemiaoccurred sporadically at low levels (< S positive cells/slide) in 19 patients (28.4%) and never resulted in CMV disease. Two of 7 patients who presented with or progressed to antigenemia of >S positive cells/slide developed fatal CMV pneumonia 8 days later. Neither patient had CMV viremia before onset of pneumonia. Thus, quantitative CMV pp6S antigenemia may be useful in guiding antiviral treatment in seropositive autograft recipients.
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The probability of developing cytomegalovirus (CMV) disease in seropositive patients is lower for patients undergoing autologous transplant than in patients after allogeneic transplant (4%-9% vs. 21%-38%) [1] [2] [3] [4] [5] [6] . While viremia, antigenemia, and detection of CMV DNA by polymerase chain reaction (PCR) may predict which allogeneic transplant patient will develop disease [6] [7] [8] [9] [10] [11] , such predictors of disease have not been well-defined in patients undergoing autologous transplant. Because the fatality rate from CMV pneumonia is comparable to that in allogeneic patients (58%-83%) [2] [3] [4] [5] [6] , a means of predicting which patients are at risk for disease would avoid prophylaxis in the majority of patients who do not need it. Since the majority of autologous patients do not have viremia before the onset of disease [5] , a screening technique that is more sensitive than the shell vial method would be of benefit.
The CMV pp65 antigenemia assay is more sensitive than either conventional or shell vial centrifugation cultures and can be quantified. This may be useful in risk-stratifying patients [12] . In allogeneic marrow transplant patients, CMV antigenemia is predictive for CMV disease and can be detected~10 days before the onset of disease, even if cultures from blood, urine, or throat are negative [8] . However, it is not known whether CMV antigenemia is also predictive for disease after autologous transplant. The quantitative nature of the test may be particularly useful in identifying autologous transplant pa-tients at risk for CMV disease, because only few patients with CMV infection progress to CMV disease (~10%) [3, 5] . Thus high-level antigenemia may indicate a higher risk for CMV disease and eliminate the need to treat every antigenemia-positive patient, many of whom may not be at risk for disease.
The purpose of this study was to evaluate the natural history of CMV pp65 antigenemia in CMV-seropositive marrow and peripheral blood stem cell (PBSC) autograft recipients. Specifically, we wanted to study the incidence of antigenemia, the onset relative to CMV viremia and disease, and whether the quantitative nature of the antigenemia assay can be used to predict CMV disease.
Patients and Methods
Patients. Pretransplant CMV-seropositive patients who received an autologous marrow or PBSC transplant at Fred Hutchinson Cancer Research Center between 1 April 1993 and 31 July 1995 were included in this study. The conditioning regimens and posttransplant care have been described [13] [14] [15] . To be included in this study, a minimum of 3 viral blood cultures and antigenemia assays at different occasions during the high-risk period for CMV reactivation [3] were required. Patients were also included if they died early and were tested weekly before death.
Virologic surveillance. Serologic status before transplant was determined by ELISA (CMV STAT; Whittaker Bioproducts, Walkersville, MD). Patients were tested weekly starting at engraftment until day 80 after transplant or until discharge from Fred Hutchinson Cancer Research Center for CMV viremia by shell vial centrifugation cultures and conventional cultures. For the antigenemia assay, leftover peripheral blood leukocytes (PBL) were used after blood cultures were initiated. In some cases, all three assays could not be done because of a low absolute neutrophil count. Heparinized blood was separated by dextran sedimentation, and PBL were divided for shell vial and tube culture inoculation and antigenemia testing. Cultures were processed as described [16, 17] . Coverslips of shell vial centrifugation cultures were stained after 16-20 hand 40 h, and tube cultures were held for at least 3 weeks. Autopsy specimens were evaluated by immunohistology for CMV and inoculated into cultures [18] . For CMV antigenemia testing, 2 cytocentrifuge slides were prepared using 1.5 X 10 5 PBL, fixed with formaldehydefNP40, and stained immediately or frozen at -20°C for subsequent staining. C1o/e 11 monoclonal antibodies directed against the lower matrix protein pp65 (Clonab; provided in part by Biotest Diagnostic, Denville, NJ) and indirect immunofluorescence were used to detect antigenemia [19] . Antigenemia results were not used to start antiviral treatment.
Definitions. CMV viremia was defined as identification of virus from blood by shell vial or conventional cultures. CMV antigenemia was defined as any positive antigenemia test. Antigenemia results were reported quantitatively as the average number of positive cells per slide [7] . CMV disease included pneumonia and gastrointestinal disease. CMV pneumonia was defined as demonstration of virus from lung tissue (by histology or culture) or in the bronchoalveolar lavage fluids by conventional and/or shell vial centrifugation culture or direct fluorescent antibodies in the presence of new or changing pulmonary infiltrates [5] . CMV gastrointestinal disease was defined as demonstration of virus from gastrointestinal tissue specimens by either culture or immunohistology.
Treatment for viremia. Patients with CMV viremia were treated with ganciclovir (5 mg/kg every 12 h for 7 days followed by 5 mg/kg every day) for 3 weeks. Patients were not treated for CMV antigenemia in the absence of viremia.
Antiviral prophylaxis. Patients received acyclovir for prophylaxis of herpes simplex virus (HSV) if they were HSV-seropositive before transplant (800 mg orally or 250 mg/rrr' intravenously every 12 h from day 5 before transplant until day 30 after transplant). Intravenous immunoglobulin (IVIG) was not given routinely except for patients with multiple myeloma who were hypogammaglobulinemic. 1 (13) 25 (42) 12 (48) 14 (27) 4 (40) 1 (100) 2 (40) 4 (25) 5 (28) 6 (67) 3 (38) 6 (35) 20 (40) 8 (53) 7 (33) 7 (41) 4 (29) 14 (47) 12 (32) 6 (46) 14 (34) 4 (44) 2 (50) 7 (10) o 7 (12) 4 (16) 3 (6) 2 (20) o o o 2 (11) 2 (22) 1 (13) 1 (6) 6 (12) 4 (27) 3 (14) o o 5 (17) 2 (5) 2 (15) 3 (7) 1 (1 I) 1 (25) 5 (8) o 5 (8) 2 (8) 3 (6) 2 (20) (6) 4 (27) I (5) o o 4 (13) 1 (3) 1 (8) 3 (7) o 1 (25) eMV antigenemia and viremia. Three hundred sixty-eight antigen tests were done on 67 CMV -seropositive patients after engraftment, a median of 5 per patient (range, 2-12). Among patients who remained negative, a median of 5 tests per patient (range, 3-12) were done. Patients' characteristics are shown in table 1. Antigenemia occurred in 26 patients (38.8%) at a median of 33 days (range, 12-74) after transplant (table 2) . Because of longer testing intervals in some patients, the true incidence of antigenemia may have been somewhat higher. The median duration of antigenemia was 1 week (range, 1-7). Two consecutive positive tests occurred in 10 patients (14.9%), and 8 patients (11.9%) had 2 consecutive tests with rising levels of antigenemia. Five (19.2%) of 26 patients with antigenemia progressed from initial levels of < 5 positive cells per slide to CMV viremia occurred in 5 patients (7.5%) a median of 30 days (range, 12-74) after transplant (table 2). Three of these patients were treated with ganciclovir for 13, 23, and 25 days; none of the 3 developed CMV disease or neutropenia. Two patients did not receive early treatment because oflate detection of viremia (conventional culture only) and detection of viremia concomitantly with the diagnosis of CMV pneumonia, respectively. In 2 patients antigenemia preceded viremia by 2 weeks, 2 had concomitant viremia and antigenemia, and 1 viremic patient had no antigenemia. Table 1 shows the presence of CMV antigenemia and viremia relative to patient characteristics. Antigenemia of> 5 positive cells per slide or viremia were associated with acute myeloid leukemia (P = .03, X 2 test), multiple myeloma (P = .03), or conditioning regimens consisting of busulfan, cyclophosphamide, and total body irradiation (TBI) or busulfan, melphalan, and thiotepa (P = .02). Patient age (P = .59), sex (P = .14), CMV disease. Three patients (4.5%) developed CMV pneumonia before day lOO after transplant. One additional patient had CMV detected by culture from a lung autopsy spedmen at day 41 after transplant. The patient's cause of death was severe regimen-related toxicity, and no pneumonia was present before death; both antigenemia and viremia were negative throughout the posttransplant course. The first of the 3 t 37-year-old woman with AML in relapse; marrow and peripheral blood stem cell transplant; conditioning regimen: busulfan, cyclophosphamide, TBI. transplant recipients, antigenemia appeared to occur somewhat earlier, that is, 30 days versus 41 days after transplant [7] . The overall majority of episodes of antigenemia were short (median , 1 week), and quantitative levels were low «5 positive cells per slide) and resolved without antiviral treatment. Antigenemia at higher levels occurred in~10% of patients , which is comparable to the incidence of viremia in this patient population [2, 5] .
Results

All
There have been no reports of effective prophylaxis strategies for CMV disease in seropositive autograft recipients. Recently, we reported that high-dose intravenous acyclovir was not effective in preventing CMV disease in this setting [5] . Because there are no identifiable risk factors for CMV disease [3, 5] , a virologic marker would be ideal to focus antiviral treatment. Although viremia was predictive for CMV pneumonia in two studies [2, 4] , at our center -90% of patients with CMV disease did not have preceding viremia [5] . Therefore , early treatment strategies based on detection of CMV by the shell vial method are unlikel y to prevent CMV disease in this setting.
The present study suggests that quantitative CMV antigenemia may be a better parameter for identifying autologous transplant recipients at risk for disease and for initiating antiviral treatment. The antigenemia assay offers two advantages that In this study, we have shown that CMV pp65 antigenemia can be detected in 38.8 % ofCMV-seropositive autologous marrow and PBSC recipients. This contrasts to 7.5% positive by viral blood culture. Antigenemia was self-limited without antiviral treatment in~75% of patients who had low-level antigenemia (< 5 positive cells per slide). Two patients who developed fatal CMV interstitial pneumonia showed a pattern of increasing levels of antigenemia before the onset of pneumonia, similar to that after allogeneic marrow transplant and after solid organ transplant [7, 12] .
The incidence of antigenemia at any level was comparable to the CMV infection rates as determined by excretion from urine, throat, and blood from previous studies (Le., -40%) [2, 3, 5] . Compared with data from seropositive allogeneic patients had CMV pneumonia at day 5 after transplant. Despite the absence of engraftment, treatment was initiated with ganciclovir, IVIG , and hematopoietic growth factors . Although neutrophil engraftment (absolute neutrophil count , 0.75 X 10-
L for 2 days) occurred at day 17 after transplant, treatment was switched to foscamet and IVIG on day 19 and continued for 2 weeks because further engraftment was slow. The patient recovered from CMV pneumonia but died of leukemic relapse.
Testing for antigenemia and viremia could not be done because of the absence of neutrophils at the time of diagnosis. Two patients developed CMV pneumonia at day 49 and 50, respectively . Both patients died despite initiation of treatment with ganciclovir and IVIG. CMV was documented by both culture and histology in autopsy specimens. The onset of viremia and antigenemia relative to the diagnosis of CMV pneumonia, type of transplant, and underlying disease in these 2 patients are depicted in table 3. Since 3 patients were treated with ganciclovir for viremia, the true incidence of CMV disease may have been somewhat underestimated. 5 may be useful for prophylaxis strategies: The high sensitivity helps identify patients at risk early and the quantitative nature of the test increases the positive predictive value for CMV disease. The latter is particularly important because only ,....., 10%-15% of patients with CMV antigenemia progress to develop CMV disease. This is markedly different from seropositive allogeneic patients with antigenemia, of whom 50%-60% progress to disease without early antiviral treatment [7] . In the present study, patients with CMV pneumonia presented with or progressed to high-grade antigenemia (table 2) . This pattern of antigenemia appears remarkably similar to that reported in solid organ and allogeneic marrow transplant patients [2, 7, 11, 12] . Thus, our data suggest that virus load as measured by antigenemia may be useful for identifying patients at high risk for CMV disease after autologous transplant. Because of the low incidence of CMV disease in seropositive autograft recipients, the optimal prophylaxis strategy to prevent CMV disease should limit the number of patients who receive early antiviral treatment and minimize the requirement for monitoring. Factors that have to be considered include the choice of the testing method, the definition of break points, and the time period of monitoring. First, the antigenemia assay appears superior to rapid culture techniques because of its higher sensitivity and quantitative nature. Whether PCR detection of CMV DNA has a role in identifying high-risk autograft recipients has not been reported. Sensitivity of the PCR may vary considerably depending on the methodology used (e.g., plasma vs. peripheral blood leukocytes, DNA vs. RNA, number of cells), but most assays are either as sensitive as or more sensitive than the antigenemia assay [10, 11, 20, 21] . Because of the high sensitivity ofPCRbased assays, a quantitative assay would probably be needed to identify patients who are likely to progress to disease [11] . Evaluation of this technique is required.
Second, if quantitative antigenemia is used, a break point must be defined. Based on the present study, we believe that initial or follow-up levels of antigenemia of > 5 positive cells per slide should be treated with a 3-week course of ganciclovir or foscarnet. This will require treatment of ,....., 10% of patients, which appears to be acceptable.
Third, monitoring should be limited to the period of highest risk because of the low incidence ofCMV disease in this patient population, the cost of monitoring, and the primarily outpatient care of autograft recipients. More than 85% of cases of CMV disease in autologous transplant patients occur between engraftment and day 65 after transplant [5] (unpublished data). Thus, monitoring for antigenemia is recommended during this time period in seropositive patients. Although it occurred in this study, CMV disease before engraftment is very rare (i.e., 1 of 3 1 autologous patients with CMV disease at our center; unpublished data).
Last, it appeared that antigenemia of > 5 positive cells per slide and viremia were more common in patients who were treated with particularly toxic conditioning regimens, such as busulfan-cyclophosphamide-TBI or busulfan-melphalan-thiotepa, probably due to a more severe posttransplant immunosuppression. It is conceivable that monitoring for antigenemia after transplant is most cost-effective in these patients; however, because it is not known whether CMV disease is also more common in patients with these conditioning regimens, this should be confirmed in a larger patient population.
In conclusion, we have shown that antigenemia can be detected in 38.8% of patients after autologous marrow and PBSC transplant. There was no difference in the incidence and pattern of antigenemia between marrow and PBSC transplants. Antigenemia preceded CMV pneumonia at levels of > 5 positive cells per slide by 8 days, even in the absence of viremia. Therefore, antigenemia could be used to initiate antiviral treatment in seropositive autograft recipients. We recommend weekly monitoring of patients for antigenemia between engraftment and day 60 after transplant, with initiation of antiviral treatment for 3 weeks if antigenemia at a level of > 5 positive cells per slide occurs.
